Celldex Therapeutics (NASDAQ:CLDX) Downgraded to “Peer Perform” at Wolfe Research

Wolfe Research downgraded shares of Celldex Therapeutics (NASDAQ:CLDX) from an outperform rating to a peer perform rating in a research report released on Friday morning, Marketbeat.com reports.

A number of other equities research analysts have also weighed in on CLDX. Wells Fargo & Company raised Celldex Therapeutics from a hold rating to a strong-buy rating in a research note on Thursday. HC Wainwright reiterated a buy rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a research report on Thursday. Stifel Nicolaus assumed coverage on Celldex Therapeutics in a research note on Tuesday, June 18th. They set a buy rating and a $58.00 price objective for the company. Finally, Cantor Fitzgerald reaffirmed an overweight rating and issued a $67.00 target price on shares of Celldex Therapeutics in a research note on Monday, September 16th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Celldex Therapeutics currently has an average rating of Buy and a consensus target price of $63.83.

Celldex Therapeutics Price Performance

Shares of CLDX opened at $33.20 on Friday. Celldex Therapeutics has a 1 year low of $22.11 and a 1 year high of $53.18. The stock has a 50 day simple moving average of $38.42 and a two-hundred day simple moving average of $38.43. The firm has a market cap of $2.20 billion, a P/E ratio of -11.61 and a beta of 1.56.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.05. The company had revenue of $2.50 million during the quarter, compared to analysts’ expectations of $1.13 million. Celldex Therapeutics had a negative net margin of 1,809.18% and a negative return on equity of 23.66%. On average, equities analysts anticipate that Celldex Therapeutics will post -2.5 earnings per share for the current year.

Institutional Investors Weigh In On Celldex Therapeutics

Several hedge funds have recently added to or reduced their stakes in the stock. UBS Group AG boosted its stake in Celldex Therapeutics by 645.9% in the 4th quarter. UBS Group AG now owns 158,092 shares of the biopharmaceutical company’s stock worth $6,270,000 after purchasing an additional 136,897 shares in the last quarter. Capstone Investment Advisors LLC purchased a new stake in shares of Celldex Therapeutics during the fourth quarter valued at approximately $502,000. Crestline Management LP increased its position in shares of Celldex Therapeutics by 6.5% during the fourth quarter. Crestline Management LP now owns 67,243 shares of the biopharmaceutical company’s stock valued at $2,667,000 after acquiring an additional 4,133 shares in the last quarter. NEOS Investment Management LLC purchased a new position in Celldex Therapeutics in the 4th quarter worth approximately $458,000. Finally, Affinity Asset Advisors LLC lifted its position in Celldex Therapeutics by 166.7% in the 4th quarter. Affinity Asset Advisors LLC now owns 400,000 shares of the biopharmaceutical company’s stock valued at $15,864,000 after acquiring an additional 250,000 shares in the last quarter.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.